Inozyme Pharma Inc., a Delaware-based company, has announced new compensation terms in light of its recent merger agreement with BioMarin Pharmaceutical, Inc. As part of the agreement, Inozyme's Board of Directors has approved transaction bonuses for key executives. Chief Financial Officer and Head of Business Development, Mr. Sanjay Subramanian, is set to receive a cash bonus of $350,000, while Dr. Matthew Winton, the Senior Vice President and Chief Operating Officer, will be awarded $320,000. These bonuses will be issued following the completion of the merger, contingent upon their continued employment until the closing date, with payments to be made within 30 days thereafter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.